BioNTech
- Revenue€482.3 MFY, 2020
- Market Capitalization€37.3 B2022-05-25
OverviewSuggest Edit
BioNTech is a biopharmaceutical company developing therapies against cancer and infectious diseases. It provides peptide manufacturing services, GMP (good manufacturing practice) manufacturing services for mRNA and cell and gene therapies, and research services. The company also develops and manufactures biomarker-based in vitro diagnostic devices (IVDD) and commercializes products through selected partners. BioNTech covers a range of platforms, including mRNA therapeutics, engineered cell therapies, antibodies, and small molecule immunomodulators.
| Type | Public | |
| Founded | 2008 | |
| HQ | Mainz, DE | Map |
| Website | biontech.de | |
| Employee Ratings |
Recent NewsAll News
- Coronavirus tally: FDA advisory panel to meet June 15 to discuss Pfizer, BioNTech and Moderna vaccines for children aged 6 months to 4 years
- Pfizer, BioNTech COVID-19 vaccine for children aged 6 months to 5 years meets EUA criteria
- BioNTech, Pfizer say they expect to have COVID-19 vaccine data for young children this quarter
- BioNTech, Pfizer seek FDA authorization of a COVID-19 booster for young children
Key People/Management at BioNTech
Sean Marett
Chief Business and Chief Commercial Officer
Ugur Sahin
Chief Executive Officer
Ryan Richardson
Chief Strategy Officer
Ozlem Tureci
Chief Medical Officer
Zach Taylor
VP of Corporate Development and Strategy
Richard Gaynor
President of BioNTech US and Chief of R&D
BioNTech Office Locations
BioNTech has offices in Mainz, Halle (Saale), Idar-Oberstein, Marburg and in 4 other locations
Mainz, DE (HQ)
An der Goldgrube 12
Halle (Saale), DE
Weinbergweg 23
Idar-Oberstein, DE
Vollmersbachstraße 66
Marburg, DE
Emil-von-Behring-Straße 76
Neuried, DE
Forstenrieder Str. 8
Planegg, DE
Am Klopferspitz 19a
BioNTech Financials and Metrics
BioNTech Revenue
BioNTech's revenue was reported to be €482.33 m in FY, 2020
| EUR | |
|---|---|
Revenue (FY, 2020) | 482.3m |
Gross profit (FY, 2020) | 677.0m |
Net income (FY, 2020) | 15.2m |
EBITDA (FY, 2020) | (43.7m) |
EBIT (FY, 2020) | (82.4m) |
Market capitalization (25-May-2022) | 37.3b |
Closing stock price (25-May-2022) | 142.6 |
Cash (31-Dec-2020) | 1.2b |
EV | 36.3b |
BioNTech's current market capitalization is €37.3 b.
Annual
| EUR | FY, 2019 | FY, 2020 |
|---|---|---|
Revenue | 108.6m | 482.3m |
Cost of goods sold | (15.9m) | (55.9m) |
Gross profit | 95.5m | 677.0m |
R&D expense | (198.9m) | (614.8m) |
Quarterly
| EUR | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|
Revenue | 27.7m | 41.8m | 67.5m |
Cost of goods sold | (5.8m) | (5.7m) | (6.8m) |
Gross profit | 22.2m | 36.9m | 69.4m |
R&D expense | (65.1m) | (95.2m) | (227.7m) |
Annual
| EUR | FY, 2019 | FY, 2020 |
|---|---|---|
Cash | 519.1m | 1.2b |
Accounts Receivable | 11.9m | 165.5m |
Prepaid Expenses | 756.0k | 898.0k |
Inventories | 12.1m | 64.1m |
Quarterly
| EUR | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|
Cash | 451.6m | 573.0m | 990.5m |
Accounts Receivable | 10.3m | 7.7m | 7.2m |
Prepaid Expenses | 980.0k | 1.0m | 724.0k |
Inventories | 9.6m | 8.6m | 12.4m |
Annual
| EUR | FY, 2019 | FY, 2020 |
|---|---|---|
Net Income | (179.2m) | 15.2m |
Depreciation and Amortization | 33.9m | 38.7m |
Inventories | (5.8m) | (49.8m) |
Quarterly
| EUR | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|
Net Income | (53.4m) | (143.9m) | (351.7m) |
Depreciation and Amortization | 8.6m | 17.4m | 26.2m |
Inventories | 2.2m | 3.2m | (508.0k) |
| EUR | FY, 2019 |
|---|---|
EV/EBITDA | -48.9 x |
EV/EBIT | -39.8 x |
EV/CFO | -36.4 x |
Revenue/Employee | 90.5k |
BioNTech Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Apta IT | ||
| BioNTech Austria Beteiligungen GmbH | ||
| BioNTech Business Services | ||
| BioNTech Cell & Gene Therapies | ||
| BioNTech Diagnostics | ||
| BioNTech Innovative Manufacturing Services | ||
| BioNTech Protein Therapeutics | ||
| BioNTech Real Estate GmbH & Co. KG | ||
| BioNTech Real Estate Verwaltungs | ||
| BioNTech Research and Development |
BioNTech Revenue Breakdown
BioNTech revenue breakdown by business segment: 30.8% from CLINICAL, 44.9% from MANUFACTURING, 21.6% from PRODUCT SALES & EXTERNAL SERVICES and 2.6% from Other
BioNTech Cybersecurity Score
BioNTech Environment, Social & Governance (ESG) Ratings
BioNTech Online and Social Media Presence
77.81k Twitter followers
BioNTech has 77.81k Twitter Followers. The number of followers has increased 0.4% month over month and increased 1.9% quarter over quarter
BioNTech's Trends
Twitter Engagement Stats for @BioNTech_Group
194
Tweets
172
Following
77.8k
Followers
3
Tweets last 30 days
127.7
Avg. likes per Tweet
100%
Tweets with engagement
BioNTech News and Updates
May 24, 2022
Coronavirus tally: FDA advisory panel to meet June 15 to discuss Pfizer, BioNTech and Moderna vaccines for children aged 6 months to 4 years
The Food and Drug Administration said Monday an advisory panel would meet June 15 to discuss use of the vaccines developed by Pfizer Inc. and German partner BioNTech SE as well as the one developed by Moderna Inc. in children aged 6 months to four years old. The announcement came after Pfizer and…
May 23, 2022
Pfizer, BioNTech COVID-19 vaccine for children aged 6 months to 5 years meets EUA criteria
Shares of Pfizer Inc. rose 0.3% and BioNTech SE rallied 1.3% in premarket trading, after the drug makers said three doses of it COVID-19 vaccine for children aged six months to five years "met all immunobridging criteria" required for Emergency Use Authorization by the U.S. Food and Drug Administr…
April 27, 2022
BioNTech, Pfizer say they expect to have COVID-19 vaccine data for young children this quarter
BioNTech SE and Pfizer Inc. said Tuesday that they expect to share data from a clinical trial evaluating their COVID-19 vaccines in children between the ages of 6 months and 5 years old sometime before the end of June. The announcement was included in a news release stating that the companies requ…
April 27, 2022
BioNTech, Pfizer seek FDA authorization of a COVID-19 booster for young children
BioNTech SE and Pfizer Inc. said Tuesday that they asked the Food and Drug Administration to authorize a COVID-19 booster dose for children between the ages of 5 and 11 years old. Boosters are already authorized for teens and adults. The companies said data from a Phase 2/3 clinical trial yielded …
April 14, 2022
Pfizer and BioNTech say data shows high immune response for COVID booster in children aged 5 to 11
Pfizer Inc. and German partner BioNTech SE said Thursday a Phase 2/3 trial of their COVID-19 vaccine booster showed a high immune response in children aged 5-to-11-years old. Data from a sub-analysis of 30 sera from the trial showed a 36-fold increase in neutralizing titers against the omicron var…
April 14, 2022
Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age
NEW YORK and MAINZ, Germany, April 14, 2022 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced positive results from a Phase 2/3 clinical trial evaluating the safety, tolerability and immunogenicity of a 10-µg booster (third) dose of the Pfizer-BioNTech CO…
BioNTech Blogs
November 29, 2020
HCP 4 Technology Platforms for COVID-19 vaccines
HCP 4 Technology Platforms for COVID-19 vaccines
admin
Sun, 11/29/2020 - 20:09
November 29, 2020
HCP 5 Biontechs Sars-Cov-2 Vaccine Candidates
HCP 5 Biontechs Sars-Cov-2 Vaccine Candidates
admin
Sun, 11/29/2020 - 20:09
BioNTech Frequently Asked Questions
When was BioNTech founded?
BioNTech was founded in 2008.
Who are BioNTech key executives?
BioNTech's key executives are Sean Marett, Ugur Sahin and Ryan Richardson.
How many employees does BioNTech have?
BioNTech has 1,941 employees.
What is BioNTech revenue?
Latest BioNTech annual revenue is €482.3 m.
What is BioNTech revenue per employee?
Latest BioNTech revenue per employee is €248.5 k.
Who are BioNTech competitors?
Competitors of BioNTech include APEIRON Biologics, Ohm Oncology and Kite Pharma.
Where is BioNTech headquarters?
BioNTech headquarters is located at An der Goldgrube 12, Mainz.
Where are BioNTech offices?
BioNTech has offices in Mainz, Halle (Saale), Idar-Oberstein, Marburg and in 4 other locations.
How many offices does BioNTech have?
BioNTech has 8 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies